Phosphogliv, capsules 50 pcs.

Pharmacodynamics

A combined agent. It has hepatoprotective, membrane stabilizing and antiviral effect.

Glycyrrhizic acid has a hepatoprotective effect due to antioxidant, anti-inflammatory effects, and effects on fibrogenesis.

Antioxidant effect. Glycyrrhizic acid binds free oxygen radicals and inhibits enzymes that initiate lipid peroxidation (LPO) in hepatocytes.

Anti-inflammatory effect. Glycyrrhizic acid reduces inflammation through its inhibitory effect on NF-kB- and TLR4-signaling pathways; inhibition of pro-inflammatory cytokine production (TNF α, IL-1, IL-6, IL-8); stimulation of anti-inflammatory cytokine production (IL-2, IL-10, IL-12).

Glycyrrhizic acid inhibits 11β-oxysteroid dehydrogenase, which contributes to an increase in endogenous cortisol in the blood (pseudocorticosteroid effect).

Influence on fibrogenesis is associated with reduction of collagen type 1 gene expression and reduction of collagen production by stellate liver cells (Ito cells), as well as destruction of activated Ito cells through the natural killer system, which helps to slow the progression of fibrosis.

Suppresses the reproduction of viruses in the liver and other organs by stimulating the production of interferons, increasing phagocytosis, increasing the activity of natural killer cells.

In case of skin lesions due to its anti-inflammatory action it limits the spread of the process and promotes the regression of the disease.

Phosphatidylcholine (the active ingredient of phospholipids) is the main structural element of cellular and intracellular membranes, restores their structure and function when damaged, having a membrane-stabilizing effect. It normalizes protein and lipid metabolism, prevents loss of enzymes and other active substances by hepatocytes and promotes restoration of liver functions.

Pharmacokinetics

Glycyrrhizic acid

. After oral administration in the intestine, under the influence of the enzyme β-glucuronidase produced by bacteria of normal microflora, glycyrrhizic acid forms an active metabolite – β-glycyrrhetic acid, which is absorbed into the systemic bloodstream. In the blood β-glycyrrhetic acid binds with albumin and is almost completely transported to the liver. Excretion of β-glycyrrhetic acid occurs mainly in bile, with residual amount in urine.

According to experimental data, phospholipids improve the lipophilic properties of glycyrrhizic acid, increasing the intensity and rate of its absorption by more than 2 times.

Phosphatidylcholine

More than 90% of ingested phospholipids are absorbed in the small intestine. Most of them are broken down by phospholipase A to 1 -acetyl-lysophosphatidylcholine, 50% of which undergoes reverse acetylation to polyunsaturated phosphatidylcholine during absorption in the intestinal mucosa. Polyunsaturated phosphatidylcholine with lymph stream enters blood, from where it is mainly bound with high density lipoproteins to liver. Pharmacokinetics in humans have been studied with dilenoleoyl phosphatidylcholine with the radioactive label -3H (choline part) and 14C (linoleic acid residue). The maximum concentration of 3H is reached after 6-24 hours, constituting 19.9% of the prescribed dose; 14C is reached after 4-12 hours, constituting 27.9%. Half-life of the choline component is 66 hours, the linoleic acid residue is 32 hours. In the stool, 2% of 3H and 4.5% of 14C are detected; in the urine, 6% of 3H and minimal amounts of 14C. Both isotopes are more than 90% absorbed in the intestine.

Indications

Hepatitis, Neurodermatitis, Alcoholism, After a course of antibiotic therapy, Psoriasis, Jaundice, Weakness and fatigue, Liver damage, Nausea, Eczema, Poisoning

– Fatty liver degeneration (hepatosis), alcohol, toxic, including drug, liver damage.

– As part of the complex therapy of viral hepatitis, liver cirrhosis and psoriasis.

Active ingredient

Glycyrrhizic acid, Phospholipids

Composition

Per capsule:

Active ingredients:

Phospholipids (Lipoid C 80) (in terms of 100% substance) (main component phosphatidylcholine 73-79%) – 65.0 mg,

sodium glycyrrhizinate (trisodium salt of glycyrrhizic acid) – 35.0 mg.

Excipients:

microcrystalline cellulose – 141.2 mg,

calcium carbonate – 204.7 mg,

Calcium stearate – 0.9 mg,

Talc – 7.7 mg,

Colloidal silica (aerosil) – 5.5 mg.

Solid gelatin capsules – 96,0 mg [Capsule composition: corpus: sunset yellow dye (E110) – 1,0000%, titanium dioxide (E171) – 1,0000%, gelatin – up to 100,0%; cap: titanium dioxide (E171) – 0.2000%, iron oxide black dye (E172) – 3.5000%, gelatin – up to 100.0%].

How to take, the dosage

It is taken orally with meals, without chewing, with a small amount of liquid.

The recommended dosing regimen for adults and children over 12 years is 2 capsules 3 times a day. The duration of use may be up to 6 months, on average 3 months.

Special Instructions

In case of high blood pressure, the drug should be stopped and a doctor should be consulted.

Influence on the ability to drive and operate machinery

The drug does not negatively affect the ability to drive vehicles and perform other work requiring increased concentration and quick psychomotor reactions.

Synopsis

hard gelatin capsules № 0, the capsule body is orange, the cap is black. The contents of the capsule – granulated powder from white with a slightly yellowish tinge to light yellow, with a slight specific smell.

Contraindications

– Hypersensitivity to glycyrrhizic acid, phosphatidylcholine or other drug components;

– Antiphospholipid syndrome;

– Pregnancy (data on effectiveness and safety are insufficient);

– Breast-feeding period (insufficient data on efficacy and safety);

– Childhood under 12 years of age (insufficient data on efficacy and safety).

Cautions

Apply with caution in patients with portal hypertension and arterial hypertension. In patients with arterial hypertension. If these diseases are present, consult a physician before starting this drug.

Precaution should be exercised in patients with portal hypertension and arterial hypertension.

Side effects

Usually the drug Fosfogliv is well tolerated, side effects are very rare, according to post-registration observation – frequency < 1/10 000.

Allergic reactions: skin rash, difficulty in nasal breathing, conjunctivitis, cough.

Cardiovascular disorders:transient (transient) increase in blood pressure, peripheral edema.

Digestive disorders:dyspepsia (belching, nausea, bloating), abdominal discomfort.

If the above symptoms occur, discontinue the drug and consult a physician.

Overdose

No cases of overdose have been recorded.

Pregnancy use

The drug is contraindicated in pregnancy and during breastfeeding (data on efficacy and safety are insufficient).